T1	Participants 126 159	Patients With Metabolic Syndrome.
T2	Participants 355 428	patients with metabolic syndrome, with and without stable statin therapy.
T3	Participants 482 820	patients with metabolic syndrome treated with IPE 4 grams/day, IPE 2 grams/day, or placebo in phase 3, randomized, placebo-controlled studies entitled: MARINE [triglyceride (TG) levels ≥500 and ≤2000 mg/dL] and ANCHOR [TG levels ≥200 and <500 mg/dL, despite low-density lipoprotein cholesterol (LDL-C) control with stable statin
T4	Participants 853 925	placebo in patients with metabolic syndrome in MARINE (n=204) and ANCHOR
T5	Participants 1847 2000	levels in patients with metabolic syndrome and high (≥200 and <500 mg/dL) or very high (≥500 and ≤2000 mg/dL) TG levels, with or without stable
